Download PDFPDF

Mass screening for coeliac disease using antihuman transglutaminase antibody assay
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests


  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

  • Published on:
    Reply to Tommasini et al: Mass Screening with Tissue Trans Glutaminase for Coeliac Disease
    • Rafeeq Muhammed, Senior House Officer, Paediatrics
    • Other Contributors:
      • A Tuladhar

    Dear Editor

    We read with interest the study by A Tommasini and colleagues on mass screening for coeliac disease using antihuman transglutaminase antibody (tTG-ab) assay. We found it surprising that only three out of ten subjects who were positive for tTG-ab and negative for anti endomysium antibodies (AMA) could be biopsied. This is due to the fact that the authors decided they would biopsy only subjects who were...

    Show More
    Conflict of Interest:
    None declared.